GlassScriptPhysician profile
Richa Gupta Jain
NPI 1881797827
$1,799.13
in general payments reported to CMS, 2019-2025
19 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.96 · 2022: $391 · 2023: $446 · 2024: $498 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.38 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $539.03 | 2022-2025 | Wegovy, Ozempic |
| Abbvie INC. | $490.88 | 2023-2025 | |
| Lilly USA, LLC | $160.64 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $118.36 | 2022 | |
| Janssen Pharmaceuticals, INC | $104.17 | 2020-2022 | |
| Abbott Laboratories | $56.25 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
| Amgen INC. | $45.17 | 2023-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $36.96 | 2024 | Veozah |
| Exact Sciences Corporation | $35.22 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $33.40 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $28.92 | 2022-2024 | Trelegy Ellipta, Arexvy |
| Axsome Therapeutics, INC. | $25.75 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $23.98 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.81 | 2024 | |
| Globus Medical, INC. | $17.71 | 2025 | Senza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $16.51 | 2020 | |
| Merck Sharp & Dohme LLC | $16.08 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.02 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richa Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.